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Ginseng, the root of Panax ginseng, is used as a traditional medicine. Despite the long
history of the use of ginseng, there is no specific scientific or clinical rationale for ginseng
pharmacology besides its application as a general tonic. The ambiguous description of
ginseng pharmacology might be due to the absence of a predominant active ingredient
that represents ginseng pharmacology. Recent studies show that ginseng abundantly
contains lysophosphatidic acids (LPAs), which are phospholipid-derived growth factor
with diverse biological functions including those claimed to be exhibited by ginseng.
LPAs in ginseng form a complex with ginseng proteins, which can bind and deliver LPA
to its cognate receptors with a high affinity. As a first messenger, gintonin produces
second messenger Ca2+ via G protein-coupled LPA receptors. Ca2+ is an intracellular
mediator of gintonin and initiates a cascade of amplifications for further intercellular
communications by activation of Ca2+-dependent kinases, receptors, gliotransmitter,
and neurotransmitter release. Ginsenosides, which have been regarded as primary
ingredients of ginseng, cannot elicit intracellular [Ca2+]i transients, since they lack
specific cell surface receptor. However, ginsenosides exhibit non-specific ion channel
and receptor regulations. This is the key characteristic that distinguishes gintonin from
ginsenosides. Although the current discourse on ginseng pharmacology is focused on
ginsenosides, gintonin can definitely provide a mode of action for ginseng pharmacology
that ginsenosides cannot. This review article introduces a novel concept of ginseng
ligand-LPA receptor interaction and proposes to establish a paradigm that shifts the focus
from ginsenosides to gintonin as a major ingredient representing ginseng pharmacology.
Keywords: ginseng, gintonin, LPAs, G protein-coupled LPA receptors, ginseng pharmacology, new paradigm
INTRODUCTION
Ginseng root (Panax ginseng CA Meyer) is one of the herbal medicines that have been widely used
in Eastern Asian countries for thousands of years. Currently, ginseng is one of the most popular
herbs used worldwide (reviewed by Jia and Zhao, 2009). Ginseng history records that it was first
considered to be a complementary treatment for “energizing the body” or as a “tonic” and is regarded
as a Chinese herbal “Qi” by Asians. Qi in relation to ginseng means energy and life force. Qi was
translated by Brekhman into another word in 1966 that describes ginseng is an “adaptogen,” which
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TABLE 1 | Summary of comparisons on membrane signal transduction between ginsenoside and gintonin.
Ginseng components Ginsenoside Gintonin Reference
Chemical structure One of triterpene dammarane
glycosides (ginseng saponin)
A complex with lysophosphatidic acid (LPA) and ginseng
proteins such as ginseng major latex-like protein 151
and ginseng major storage protein
Hwang et al. (2012), Nah (2014)
Endogenous presence in animals No Yes(LPAs present in brain, platelet, serum, and body
fluids)
Hwang et al. (2012)
Cell surface membrane binding
protein
Interact with ion channels and
receptors with non-specific manners
LPA receptors Hwang et al. (2012), Nah (2014)
Signal transduction pathway
systems
No Pertussis toxin-sensitive and -insensitive G proteins
Phospholipase C and IP3 receptor activation
Hwang et al. (2012), Nah (2014)
Second messenger production
and influence to effector systems
No [Ca2+]i transient induction Ca2+-dependent various
kinase, ion channels and receptors
Hwang et al. (2012), Nah (2014)
Concentration requirement for in
vitro cellular responses
High concentration of ginsenoside
(mM)
Low concentration of gintonin (<nM) Hwang et al. (2012), Nah (2014)
Capability of intracellular and
intercellular communications
No Yes (through regulations of intracellular ion channels or
receptors, glio- or neuro-transmitter release)
Hwang et al. (2015), Kim et al.
(2015a)
means, “ginseng extract is believed to increase the body’s ability to
resist the damaging effects of stress and promote or restore normal
physiological functions” (Brekhman et al., 1966). Currently, the
term “adaptogen” is rather vague in terms of modern medicine,
and Brekhman et al. (1966) did not provide further information
on the active ingredient of ginseng that could play the role
of an adaptogen. Instead, the adaptogenic effects of ginseng
were translated into the following claims: promotes stamina,
increases resistance to disease including cancer, improves physical
performance as an ergogenic aid, reduces physical fatigue and
mental stress, improves mental awareness, restores and enhances
sexual function, and finally, increases life expectancy. However,
evidence supporting these claims is still lacking and further
studies demonstrating these effects are necessary.
Advanced analytical techniques have revealed that ginseng
contains bioactive components such as ginsenosides, acidic
polysaccharides, and polyacetylenes as well as other minor
components (reviewed by Leung and Wong, 2010). Ginsenosides
and their chemical structures were first discovered and identified
in ginseng, and are considered as its primary component
(Shibata et al., 1965). Ginsenosides are triterpene saponins that
are found only in ginseng species. The molecular weights of
ginsenosides are in the 1000 Da range, which makes it is easy to
isolate them from ginseng (Figure 3). The isolated ginsenosides
have a peculiar bitter, sweet, or bittersweet aroma and taste
compared to other components. Most ginseng efficacy-related
studies have focused on the actions of its saponins (reviewed
by Leung and Wong, 2010). However, accumulating evidence
show that these identified components of ginseng, especially
the ginsenosides, do not represent the complete diversity of
ginseng pharmacology. In particular, ginsenosides does not
fully exhibit systemic actions in vitro and in vivo that can
be associated with all the underlying molecular mechanisms
observed in ginseng pharmacology (Table 1; reviewed by Nah,
2014).
Other components of ginseng except those noted above are
relatively unknown, despite the claims of its diverse efficacy.
A key clue suggesting the presence of a novel ingredient in
ginseng is the crude ginseng total saponin (cGTS) fraction,
which when prepared before further isolation of individual
ginsenosides, contains approximately 50% of ginsenosides by
weight. The biological properties of the rest of the components
of the cGTS fraction besides ginsenosides were previously
unknown. Interestingly, the cGTS fraction was shown to mimic
G protein-coupled receptor (GPCR) ligands such as acetylcholine
by activating the endogenous Ca2+-activated Cl  channel
in Xenopus oocytes (Choi et al., 2001a,b; Lee et al., 2004).
Furthermore, the unidentified ingredients in cGTS that induced
Ca2+-activated Cl  channel activation were not ginsenosides
but rather, were similar to an unidentified GPCR ligand (Pyo
et al., 2011). Further studies showed that ginseng contains several
types of lysophosphatidic acids (LPAs), which are endogenous
phospholipid-derived growth factors in animals. In ginseng,
the LPAs are isolated as a complex with ginseng proteins that
stabilizes and prolongs their activity, and delivers them to their
cognate receptors, which is a characteristic that distinguishes
them from other plant-derived LPAs (Hwang et al., 2012; Choi
et al., 2015; Figure 1). Gintonin, a complex of ginseng LPAs
and proteins, activates LPA GPCRs with a high affinity (Hwang
et al., 2012). This was the first demonstration that ginseng also
contains GPCR ligands. Interestingly, the above traditional claims
of ginseng efficacy overlap with the known biological effects
of LPAs in many aspects (Table 2). Gintonin via LPA receptor
activation provides further systemic evidence of the diverse
effects of ginseng that ginsenosides do not (Figure 2; reviewed
in Nah, 2012, 2014). The subsequent sections in this review
illustrate the differences in the mode of action of ginsenosides
and gintonin, and propose a necessary re-establishment of the
representative ingredient of ginseng that shifts the claims for
the pharmacological properties of ginseng from ginsenosides to
gintonin.
FUNCTIONAL LIGAND OF GINTONIN BUT
NOT GINSENOSIDES IS ENDOGENOUS TO
BOTH ANIMAL AND PLANT SYSTEMS
Human beings have isolated and used pharmacologically active,
plant-derived ligands for a long time. Some plant-derived ligands
mimic the physiological/pharmacological effects of endogenously
Frontiers in Pharmacology | www.frontiersin.org October 2015 | Volume 6 | Article 2452
Choi et al. A new paradigm in Ginseng pharmacology
FIGURE 1 | H146 and H148 are key amino acids for LPA C18:2 binding to ginseng major latex-like protein 151. Recognition of lysophosphatidic acid by
ginseng major latex-like protein 151 (A) Superposition of ginseng major latex-like protein 151 (GLP; green) and lowest energy major latex protein 28 conformer
(yellow). The mutated residues in GLP are represented by red sticks. (B) The electrostatic molecular surface of GLP modeled LPA C18:2. The positions of the residues
that recognize LPA C18:2 are labeled. The His147 and His148 residues are important for the interaction between GLP and LPA and for activation of the LPA receptor.
Adapted from Choi et al. (2015).
TABLE 2 | Summary of comparison in in vitro and in vivo activities of gintonin or LPA.
Gintonin LPA Reference
In vitro
Receptor LPA LPA Hwang et al. (2012)
G proteins PTX-sensitive and in-sensitive G proteins PTX-sensitive and in-sensitive G proteins Hwang et al. (2012)
Second messenger and effector systems PLC-IP3-Ca2+ and Ca2+-dependent cellular events PLC-IP3-Ca2+ and Ca2+-dependent
cellular events
Hwang et al. (2012),
Nah (2012)
Cellular effects Proliferation, migration, neurite retraction, and
morphological changes
Proliferation, migration, neurite retraction,
and morphological changes
Hwang et al. (2012)
Synaptic transmission, gliotransmitter, Gliotransmitter and neurotransmitter release Neurotransmitter release Hwang et al. (2015),
and neurotransmitter release Kim et al. (2015a)
In vivo
Nervous systems Anti-Alzheimer’s disease: attenuation of amyloid
plaque formation and restoration of cholinergic
system damaged by Ab
Nervous system development, cognition Hwang et al. (2012)
Cardiovascular systems – Angiogenesis
Reproductive systems – Spermatogenesis and Embryo implantation
through LPA3 receptor
Hair growth – Hair growth through LPA6 receptor
Anti-cancer action Anti-metastasis though inhibition of autotoxin activity – Hwang et al. (2013)
occurring ligands in animals. However, plant-derived active
ligands acting on animal cells usually differ from endogenous
ligands in their chemical structures. Interestingly, LPAs are
commonly found in both animal and plant systems with the same
chemical structure. In animals, Vogt (1957) first found that LPA
exists in the intestine and brain lipids. Tokumura et al. (1978)
first reported the presence of free LPA in plant soybean lecithin.
Plant systems synthesize LPAs and plant-derived LPAs such as
gintonin, can serve as LPAGPCR ligands in animal cells, although
plant LPAs are merely metabolic intermediates in de novo lipid
synthesis in plant cell membranes or for glycerophospholipid
storage (Millar et al., 2000). Recent studies show that LPA is
found in most cell types such as neuronal and glial and non-
neuronal cells such as adipocytes and fibroblasts (Tigyi and Parrill,
2003). LPA has also been detected in body fluids such as serum,
saliva, and follicular fluid where it performs diverse biological
functions (Moolenaar, 1994). LPAs like gintonin exist in both
animals as endogenous ligands and plant systems as metabolic
intermediates, whereas ginsenosides exist only in ginseng but not
animal systems. Although the chemical structure of ginsenosides
is similar to that of the steroidal backbone, they are actually
triterpenoid saponins that differ from steroids found in animals.
Gintonin is an exogenous functional ligand for LPA receptors.
This is the first feature distinguishing gintonin from ginsenosides.
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FIGURE 2 | Schematic diagram that gintonin-mediated in vitro cellular effects through LPA receptors in neurons and astrocytes is linked to in vivo
pharmacological effects. The primary action of gintonin produces second messenger Ca2+ via LPA receptor activations and regulates Ca2+-dependent to various
ion channels and receptors regulations, and glio-transmitter and neuro-transmitter release. The ensuing inter-cellular communications via the released
neurotransmitters (i.e., acetylcholine or glutamate) can be related to the pharmacological effects that can finally be linked to improvement of learning and memory in
nervous system (Kim et al., 2015c). Gintonin also exhibits pharmacological effect against Alzheimer’s disease by attenuating b-amyloid plaque formation and by
ameliorating cognitive dysfunction via the activation of non-amyloidogenic pathway and by restoring cholinergic systems that were damaged by b-amyloid in
transgenic Alzheimer’s disease animal model (Hwang et al., 2012; Kim et al., 2015b). In astrocytes, gintonin-mediated ATP and glutamate release can be coupled to
regulations of neuronal activity (Kim et al., 2015a). In addition, gintonin as exogenous LPA induces various cellular effects such as migration and proliferation of cells
as LPAs do through LPA receptor activations. Gintonin also exhibits anti-metastasis activity via inhibition of autotaxin (ATX) activity. ACh, acetylcholine; AChE,
acetylcholine esterase; sAPPa, soluble amyloid precursor protein a; ATX, autotaxin; ChAT, choline acetyltransferase; Glu, glutamate.
GINTONIN INTERACTS WITH PROTEINS
ON ANIMAL CELL SURFACE MEMBRANES
Most of animal- and human-derived first messenger endogenous
ligands such as hormones or neurotransmitters have binding or
interaction protein(s) on cell surface membranes, and each ligand
binds to its specific surface protein called a receptor (Kihara et al.,
2015). The binding of a ligand to its receptor initiates or translates
extracellular information to intracellular sites and transfers
extracellular information even at very low concentrations.
For example, most hormones and neurotransmitters such as
peptides, proteins, catecholamines, and acetylcholine elicit
cellular responses at less than nanomolar concentrations (Kihara
et al., 2015). Extracellular information may also be transferred
to intracellular sites by permeation of ligands into the cell where
they bind to intracellular receptors. For example, most steroid
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FIGURE 3 | Chemical Structure of ginsenoside Rg3. Glc,
glucopyranoside. Ginsenoside Rg3 and other ginsenosides differ in the three
side chains and carbohydrates attached to a common steroid-like ring.
Subscripts indicate the carbons in the glucose rings that link the two
carbohydrates. Adapted from Nah et al. (2007).
hormones act on intracellular receptors (reviewed by Helzer
et al., 2015). Animal- or plant-derived bioactive ingredients also
exert their effects by acting on their respective receptors located
on the cell surface or intracellularly in animal systems. These
effects may be agonistic or antagonistic. Human beings have
used plant-derived ligands for medicinal purposes since ancient
times. Representative plant-derived medicinally active ligands
include morphine as an analgesic isolated from the poppy plant
and cannabinoids as an anti-glaucoma agent from marijuana,
respectively (reviewed by Cichewicz, 2004).
Interestingly, ginseng has a long history of use in traditional
herbal medicines but its pharmacology and specific therapeutic
applications are not well defined (reviewed in Nah, 2012, 2014).
This might be due to a lack of information on the bioactive
components of ginseng with the exception of ginseng saponins,
which are well characterized (reviewed by Nah, 2012, 2014).
Ginsenosides are the first recognized bioactive components of
ginseng (reviewed by Nah et al., 2007); however, their current
designation as the representative bioactive components of ginseng
has several shortcomings. First, ginsenosides have no known
specific extracellular or intracellular receptors in animal cells
(Nah, 2014), which do not show any spontaneous cellular
responses following treatment with ginsenosides. To observe
the pharmacological effects of ginsenosides, cells must be pre-
stimulated by electrical currents, excitatory ligands, or other
treatments or subjected to injuries like hypoxia or ischemia,
in the case of organs (Nah, 2014). Second, ginsenosides must
be applied at high micromolar concentrations ( 30–97 mM
in EC50 or IC50) to elicit any physiological or pharmacological
effects compared to other endogenous or exogenous ligands
(Choi et al., 2002 Nah et al., 2014). Third, the effects of
ginsenosides are miscellaneous, non-selective, and receptor-
independent (Figure 4). Ginsenosides lack specific membrane
target proteins and interact non-selectively and indiscriminately
with various plasma membrane proteins such as ion channels and
receptors (Figure 4; reviewed by Nah, 2014). Gintonin as a first
messenger isolated from ginseng, binds only to cell surface LPA
receptors with a high affinity and elicits cellular responses at less
than nanomolar or nanomolar concentration ranges (0.45–18 nM
in EC50), to primarily activate [Ca2+]i transients (Figure 2; Pyo
et al., 2011; Hwang et al., 2012; Nah, 2012). This is the second
characteristic that distinguishes gintonin from ginsenosides.
GINTONIN HAS A SPECIFIC SIGNALING
PATHWAY FOR ACTIVATION OF SECOND
MESSENGER
Endogenous or exogenous bioactive ligands activate cell surface
receptors and initiate a cascade that amplifies the first messenger
action via signal transduction pathways (reviewed by Hofmann
and Palczewski, 2015). First, the membrane signaling proteins are
activated, and then they mediate subsequent reactions, following
membrane receptor activation. Guanosine triphosphate (GTP)-
binding proteins are involved in the first step in transferring
extracellular information from the first messengers to cytosolic
effector systems, which include adenylate cyclase, phospholipase
C (PLC), protein kinase C, and others. Finally, the activation or
inhibition of effector systems is coupled to final secondmessenger
production or inhibition such as cyclic adenosinemonophosphate
(cAMP) production or Ca2+ release from storage. Endogenous or
exogenous bioactive ligands activate receptors that are specifically
coupled to cAMP, Ca2+, or other second messenger systems
depending on the receptor types (reviewed by Clister et al., 2015).
Ginsenosides alone do not elicit any cellular responses related
to signal transduction pathways (Nah et al., 1995) and only
affect intracellular Ca2+ or other cation concentrations when
neuronal cells are pre-depolarized or neuronal receptors are
prestimulated by excitatory ligands. For example, ginsenosides
inhibit NMDA receptor-mediated Ca2+ influx only in the
presence ofNMDA (Lee et al., 2006). Ginsenoside action is limited
to the membrane (Table 1; Figures 3 and 4). However, gintonin
treatment induces spontaneous responses in cells that express
endogenous LPA receptors to elicit [Ca2+]i transients. Gintonin
modulates membrane signal transduction pathways and effector
systems to induce [Ca2+]i transients such as pertussis toxin-
sensitive and -insensitive Gai/o, Ga12=13, Gaq=11, and cytosolic
PLC and inositol triphosphate (IP3) receptors (Table 1;Hwang
et al., 2012). Gintonin but not ginsenosides utilizes Ca2+ to exert
further diverse Ca2+-dependent intracellular effects. This is the
third feature that distinguishes gintonin from ginsenosides.
GINTONIN USES VARIOUS EFFECTOR
SYSTEMS TO AMPLIFY CELLULAR
EFFECTS
Gintonin acts on LPA receptors to activate cells via a transient
increase in [Ca2+]i levels (Hwang et al., 2012). There are
numerous proteins that are dependent onCa2+ for their activation
including various kinases, membrane ion channels, and receptors
(reviewed by Berridge et al., 1998). Gintonin-mediated induction
of [Ca2+]i transients is coupled to Ca2+-dependent activation
of various kinases [such as Ca2+/calmodulin-dependent protein
kinase II (CaM kinase II), protein kinase C, and tyrosine kinase],
ion channels (Ca2+-activated Cl , Ca2+-activated K+, delayed
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FIGURE 4 | Schematic diagram on ginsenoside-induced various ion channel and receptor regulations on cell surface membrane. Ginsenoside (i.e.,
ginsenoside Rg3) actions on cell surface ion channels and receptors show several characteristics. First, ginsenoside shows various non-specific regulations of ion
channels and receptors as illustrated here. However, overall actions of ginsenoside decrease the cellular excitability of excitable cells by inhibiting cation influx (i.e.,
Ca2+ and Na+ channel activity inhibitions or K+ channel activation and ligand-gated ion channel inhibitions such as 5-HT3, nACh, and NMDA receptors), and by
stimulating anion influx (i.e., GABAA and glycine receptor channel activation). Second, ginsenoside-induced ion channel and receptor regulations achieve via
interaction with ion channel pore, channel pore entryway, and share channel blocker or toxin biding sites through site-directed mutagenesis studies (Nah, 2014).
Third, ginsenoside itself does not induce ion channel or receptor inhibition or activation at resting state, without preceding stimulations of ion channel or receptors by
depolarization or receptor ligand treatment. Thus, the biological or pharmacological effects of ginsenoside could be observed when cells or organs are stimulated
beyond normal state rather than receptor mediation like gintonin.
rectifier K+, and Kv1.2), receptors (NMDA and P2X1), hormone
secretion (such as dopamine), gliotransmitters [such as adenosine
triphosphate (ATP) and glutamate], and neurotransmitter release
(such as acetylcholine and glutamate; Shin et al., 2012; Choi
et al., 2013b; Lee et al., 2013b; Hwang et al., 2015; Kim et al.,
2015a). Ginsenosides do not have a specific signaling pathway for
inducing cellular activation and neurotransmitter release. Instead,
ginsenosides regulate various ion channels and receptors non-
selectively (Figure 4; reviewed by Nah, 2014). Recent studies
showed that ginsenosides inhibit ion channels and receptors by
directly interacting with amino acids at channel pores similar to
channel blockers or toxins (reviewed in Nah, 2014). Ginsenosides
simply negatively affect cytosolic ion concentration by cellularly
inhibiting Ca2+ or Na+ influx but by enhancing GABAA and
glycine receptor channel Cl  currents (Lee et al., 2008, 2013a;
Choi et al., 2009). Ginsenosides have no intracellular mediators
that further amplify their effects but regulate ion channel activities
by directly interacting with membrane ion channel proteins
(reviewed by Nah, 2014). Gintonin but not ginsenosides acts via
a second messenger (Ca2+) and shows a consistent pattern in
its actions that always involves cytosolic Ca2+, which mediated
its pharmacological effects through various kinases, ion channels,
and receptors. This is the fourth characteristic that distinguishes
gintonin from ginsenosides.
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GINTONIN MEDIATES CELL–CELL
NERVOUS SYSTEM COMMUNICATIONS
The most important characteristic of endogenous or exogenous
ligands is the ability to transfer information from one cell to
another to induce subsequent biological effects. Hormones or
neurotransmitters play a role in information transfer between
cells or from cells to organs (reviewed by Berridge et al.,
2003). The elevation of [Ca2+]i by GPCR ligand-mediated
activation is coupled to neurotransmitter release into the synaptic
cleft where it delivers presynaptic information to postsynaptic
neurons (reviewed by Berridge et al., 1998). The gintonin-
mediated [Ca2+]i transient is also coupled to gliotransmitter
or neurotransmitter release (Hwang et al., 2015; Kim et al.,
2015a). Furthermore, gintonin-mediated release of hormones
and neurotransmitters can affect other neighboring or remote
cells, resulting in long-term potentiation (LTP) and enhancement
of synaptic transmission with subsequent cognitive enhancing
effects (Kim et al., 2015c; Park et al., 2015). Therefore, gintonin
has specific modulating systems for cell–cell communications
via neurotransmitter release in the hippocampus, ultimately
leading to biological effects like enhancement of cognitive
behavior (Kim et al., 2015c; Park et al., 2015). Ginsenosides
themselves do not elicit [Ca2+]i transients and are not capable
of inducing intracellular and intercellular communications (Nah
et al., 2007). This is the fifth feature that distinguishes gintonin
from ginsenosides. However, ginsenosides might have several
other receptor-independent cellular effects that are not related to
cell surface receptor activation. For example, ginsenosides show
antioxidant effects and reduce free radical-induced cell damage,
which are also observed with most natural products such as fruits
and vegetables (reviewed by Liu, 2012). Ginsenosides also inhibit
platelet aggregation (reviewed by Mousa, 2010) and enhance
non-specific immune responses, which are also observed with
most mushrooms with immunomodulatory activities (reviewed
by Kang and Min, 2012). The functional comparisons of gintonin
and ginsenosides are summarized in Table 1.
GINTONIN BUT NOT GINSENOSIDES HAS
A CLEAR MODE OF IN VITRO AND IN VIVO
PHARMACOLOGICAL ACTIONS VIA LPA
RECEPTORS
Hecht et al. (1996) first reported LPA as a ligand of the ventricular
zone gene-1, which is abundantly expressed in the ventricular
zone during mammalian brain neurogenesis. Since then in
subsequent studies, six LPA receptor subtypes have been further
cloned on the surface of various cells, andmost organs also widely
express endogenous LPA receptor subtypes (Yung et al., 2015).
LPA and its receptors play important roles from the embryonic
to adult stage as well as in nervous and non-nervous systems
including the brain, cardiovascular, reproductive, and immune
systems (Table 2).
Although the LPAs content of gintonin originates fromginseng,
gintonin uses the same signaling transduction pathways as
animal-derived LPA does in the induction of [Ca2+]i transients
in neuronal and non-neuronal cells as mentioned above (Hwang
et al., 2012). The acute or short-term effects of gintonin but
not ginsenosides regulates various Ca2+-dependent ion channels
and receptors, in vitro (Shin et al., 2012; Choi et al., 2013a,b,
2014; Lee et al., 2013b; Hwang et al., 2015). The regulation of
ion channels and receptors is coupled to cellular effects. For
example, in the nervous system, the gintonin-mediated [Ca2+]i
transient is coupled to the release neurotransmitters such as
acetylcholine, dopamine, and glutamate (Hwang et al., 2015; Kim
et al., 2015a; Park et al., 2015). Gintonin-mediated Kv1.2 channel
inhibition and NMDA receptor activation are closely associated
with LTP induction and enhancement of synaptic transmission in
the mouse hippocampus (Park et al., 2015). In addition, gintonin
but not ginsenosides stimulates cell proliferation and migration
in human umbilical vein endothelial cells and induces neurite
retraction via pertussis toxin-sensitive and -insensitive G proteins
(Hwang et al., 2012, 2015).
Kim et al. (2015c) observed that hippocampal LTP increased in
mice that were previously treated with gintonin for 7 days orally
compared to saline-treated mice. In addition, the hippocampi
of mice that were previously treated for 7 days with gintonin
showed increased expressions of learning and memory-related
proteins such as phosphorylated cAMP-response element binding
(pCREB) protein and brain-derived neurotrophic factor (BDNF).
Finally, in a behavioral study, gintonin administration improved
fear memory retention in the contextual fear-conditioning test in
mice (Kim et al., 2015c).
Regarding the hippocampal cholinergic system, long-term
administration of gintonin to wild-type mice increased the
immunoreactivity of hippocampal choline acetyltransferase,
which is responsible for acetylcholine synthesis (Kim et al.,
2015b). This observation indicates that gintonin treatment not
only stimulates acetylcholine release but also induces an increase
in the level of the enzyme related to acetylcholine synthesis. In
behavioral tests, gintonin treatment also restored scopolamine-
induced memory dysfunction in passive avoidance and Morris
water maze tests (Kim et al., 2015b). Gintonin showed boosting
effects on the brain cholinergic system. Therefore, long-term
oral administration of gintonin enhances cognitive functions
via activation of cognition related proteins and the cholinergic
system.
Astrocytes are considered to have simple structural functions
and act as metabolic supporters and protector of neurons in the
central nervous system.Recent studies show that astrocytes release
gliotransmitters, which modulate neighboring neuronal activities
by forming a tripartite synapse with neurons (Araque et al., 2014).
LPA receptors are abundantly expressed in astrocytes (Tabuchi
et al., 2000; Shano et al., 2008). In addition, astrocytes release
LPA in the hippocampus, which then interacts with LPA receptor
on neuronal presynaptic sites to induce hippocampal excitation
by stimulating glutamate release (Trimbuch et al., 2009). In
primary cortical astrocytes, gintonin but not ginsenosides
induces a [Ca2+]i transient via LPA receptor signaling pathways.
Gintonin as well as LPA stimulates the release of gliotransmitters
such as ATP and glutamate, and this effect is also [Ca2+]i-
sensitive because [Ca2+]i-chelators abolish gintonin-mediated
gliotransmitter release (Kim et al., 2015a). Therefore, astrocytes
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produce LPA for release and gintonin as an exogenous LPA source
stimulates gliotransmitters via LPA receptors. These results imply
that LPA receptors in astrocytes may be positive autoreceptors.
The LPA released from astrocytes modulates neuronal activities
directly via interaction with LPA receptors on neurons (Trimbuch
et al., 2009) or indirectly by releasing gliotransmitter following
the activation of astrocytic LPA receptors (Araque et al., 2014).
Gintonin as an exogenous LPA source might control neuronal
activity in two ways. One way is directly through interactions
with neuronal cell surface LPA receptors, and the other is indirect
via induction of gliotransmitter release from astrocytes expressing
LPA receptors. Therefore, gintonin exert its effects in the nervous
system via regulation of neuronal and astrocytic systems through
the release of gliotransmitters and neurotransmitters (Figure 2).
EXOGENOUS GINTONIN EXERTS HEALING
EFFECTS IN INJURED ORGANS
Lysophosphatidic acid production, release, and receptor
expression levels have been observed to change in
pathophysiological conditions following cellular or organs injury
or trauma. In non-nervous systems, injury to blood vessels
activates platelets to release LPA, induces platelet aggregation,
and facilitates blood coagulation to stop bleeding (Yoshida et al.,
2003; Bolen et al., 2011). Autotaxin (also called lysoPLD, which
produces LPA from lysophosphatidylcholine) activity for LPA
production increased in the aqueous humor of the eye following
corneal damage and ischemia-reperfusion injury of the retina
increased LPA release (Liliom et al., 1998; Savitz et al., 2006).
Autotaxin activity for LPA production also increased in patients
with cancers including breast, melanoma, and ovarian (Leblanc
and Peyruchaud, 2015). These observations indicate that the
endogenous LPA–LPA receptor system participates in healing
processes in blood vessels and the eye. LPA-producing enzymes
(autotaxin) are involved in pathophysiological conditions such
as cancer progression (Goldshmit et al., 2010). We observed that
gintonin stimulated the in vitro proliferation and migration of
human corneal epithelial cell for wound healing via LPA receptor
activation (Hwang et al., 2012). Interestingly, gintonin strongly
inhibits autotaxin activity released from melanoma cells, and
inhibits cell motility and migration but gintonin had almost no
effects on cell proliferation (Hwang et al., 2013). In addition,
oral administration of gintonin inhibited metastasis to the lung
following administration of cells via the tail vein, and inhibited
tumor growth after subcutaneous transplantation of melanoma
cells in mice. Gintonin treatment also significantly decreased
necrosis, mitosis, pleiomorphisms, and vascularity in tumor
tissues (Hwang et al., 2013).
In the nervous system, there have been several reports
that LPA concentration and receptor level or autotaxin
expression are also altered under pathophysiological conditions
in human. Plasma LPA concentration is elevated in patients with
ischemic cerebrovascular disease (Li et al., 2008). Human brain
neurotrauma caused an increase in LPA receptor expression level
(Savaskan et al., 2007; Frugier et al., 2011). In addition, patients
with Alzheimer-type dementia showed increased autotaxin
expression in their frontal cortices compared to normal brains
(Umemura et al., 2006). Treatment with gintonin as an exogenous
LPA source exhibited anti-Alzheimer’s disease (AD) activity via
LPA receptors. Gintonin-mediated LPA receptor activation is
coupled to an increase in the soluble amyloid precursor protein a
(sAPPa) release instead of neurotoxic b-amyloid (Ab) formation
in neuroblastoma SH-SY5Y cells but ginsenoside showed no such
effects (Hwang et al., 2012). Long-term oral administration of
gintonin decreased neuropathies by Ab plaque formations in
the cortices and hippocampi of wild-type mice and restored Ab-
induced memory dysfunctions in a transgenic AD animal model
(Hwang et al., 2012).
Acetylcholine is an important neurotransmitter involved in
cognitive brain functions such as learning and memory, and the
brains of patients with AD show dysfunction of the cholinergic
system (i.e., a decrease in brain acetylcholine concentration and
choline acetyltransferase activity but increase in acetylcholine
esterase, which is an enzyme for acetylcholine hydrolysis).
Long-term oral administration of gintonin also attenuated
cholinergic dysfunctions in the hippocampus by increasing
brain acetylcholine concentrations and choline acetyltransferase
activity and decreasing acetylcholine esterase activity (Kim et al.,
2015b). Long-term oral administration of gintonin contributed to
the restoration of adult brain cholinergic dysfunctions by Ab itself
and Ab-induced cholinergic dysfunctions in a neurodegenerative
AD animal model (Kim et al., 2015b).
Considering the previously described in vitro and in vivo
actions of gintonin, the exogenous application of gintonin may
contribute to restoring the condition of damaged cells or injured
organs via regulation of LPA receptors and autotaxin activity. The
functional comparisons of gintonin and LPA are summarized in
Table 2.
PERSPECTIVES AND CONCLUDING
REMARK
The modern interpretations of ginseng pharmacology have
advanced tremendously alongside isolation of its components
over the last few decades. However, a number of traditional
herbal medicine practitioners still believe that the efficacy of
ginseng is a mystery. In early ginseng studies in Japan, Russia,
and other countries conducted prior to 1960, investigators focused
on ginsenosides in an attempt to explain ginseng pharmacology,
since they were first identified as components. However, with over
five decades of studies on ginsenosides, accumulating evidence
shows that the current ginseng pharmacology extends beyond
effects that can be attributed to ginsenosides. In other words,
attributing the wide variety of pharmacological effects exhibited
by ginseng solely to the ginsenosides, is no longer plausible
(Figure 3). To advance the elucidation of ginseng pharmacology
and development of ginseng-derived medicines, a component
with specific targets (i.e., receptor) needs to be identified.
Gintonin, which targets LPA receptors unlike ginsenosides, could
be a lead candidate for the development of ginseng-derived
medicines.
Gintonin, for the first time, can be introduced as a candidate for
the novel ligand-receptor interaction concept in the new modern
description of ginseng pharmacology. Most therapeutic effects of
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modern medicines are attributed to ligand-receptor interactions.
Currently, studies on gintonin, which is an LPA GPCR ligand,
provide diverse evidences of its involvement in the effects of
ginseng and, therefore, ultimately explain its pharmacology.
In addition, since the activation of LPA receptors by LPA
exhibit a variety of biological effects not observed with ginseng,
we can further expand ginseng pharmacology by elucidating
the gintonin-LPA receptor relationship (Table 2). Furthermore,
gintonin could serve as a newly defined up-to-date adaptogenic
component of ginseng and a novel candidate to fit the description
of “a healing molecule that can restore disruption of physiology
functions caused by damage or disease, via LPA receptors or
autotaxin regulation.”
Ginseng extract is also considered a complementary and
alternative medicine. Currently, more than 50% of medicines
used in animals and human beings act via GPCRs, and these
receptors along with their ligands are still targets for novel
drug development. Many international companies have also
concentrated their efforts on the research and development of
drugs that act via LPA GPCRs (Llona-Minguez et al., 2015).
Gintonin was shown to ameliorate the neurodegenerative AD
in an animal model via LPA receptors. Finally, gintonin could
be a major lead candidate for development as a ginseng-derived
natural medicine and not simply just a complementary and
alternative functional food or medicine.
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